Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy.
A 10-year follow-up analysis has been performed on the cohort of 13 previously reported inflammatory breast cancer patients treated with chemotherapy, surgery, and allogeneic tumor cell/BCG vaccine. Follow-up of this duration is uncommon in the literature. Data indicate an apparent plateau of the survival curve at about 5 years, with 4 of 13 patients (31%) still alive after 10 years. Also noted is a long-term survival of an off-protocol patient with metastatic breast cancer treated with chemotherapy and vaccine. Although the role of vaccine cannot be directly determined from this study, this trial did demonstrate that long-term survival is a feasible goal for a significant fraction of patients with inflammatory breast cancer.
Wiseman
C L
CL
Los Angeles Oncologic Institute, St. Vincent Medical Center, California, USA.
D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D016233:Immunotherapy, Active; D008408:Mastectomy; D008875:Middle Aged; D016019:Survival Analysis; D017741:Survivors; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil